Thiazolidinediones and clinical outcomes in type 2 diabetes

Lancet. 2009 Jun 20;373(9681):2088-90. doi: 10.1016/S0140-6736(09)61029-1. Epub 2009 Jun 6.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cholesterol, LDL / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Therapy, Combination
  • Hospitalization / statistics & numerical data
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / therapeutic use
  • Myocardial Infarction / mortality*
  • Pioglitazone
  • Randomized Controlled Trials as Topic
  • Rosiglitazone
  • Stroke / mortality*
  • Sulfonylurea Compounds / therapeutic use
  • Thiazolidinediones / therapeutic use*

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypoglycemic Agents
  • Sulfonylurea Compounds
  • Thiazolidinediones
  • Rosiglitazone
  • Metformin
  • Pioglitazone